A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors

NCT06859762 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

220

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumor

Interventions

DRUG: YL217
DRUG: YL217
DRUG: YL217

Sponsor

MediLink Therapeutics (Suzhou) Co., Ltd.